title: Differentiation of central cholecystokinin receptor binding sites using the non-peptide antagonists MK-329 and L-365,260.
abstract: Cholecystokinin (CCK) receptor binding was measured in rodent and primate brain and spinal cord using 125I-Bolton Hunter CCK-8 (125I-BH-CCK) and the selective non-peptide CCK antagonists MK-329 and L-365,260. In homogenate binding studies, L-365,260 displayed nanomolar affinity for CCK-B receptors in the cerebral cortex of several species including man (pIC50 congruent to 8.2) but showed low affinity for CCK-A receptors in the rat pancreas (pIC50 congruent to 6.3). By contrast, the CCK-A antagonist MK-329 showed the reverse selectivity (cortex: pIC50 congruent to 6.9, pancreas: pIC50 = 9.6). In autoradiographs of rat and monkey brain. 125I-BH-CCK binding was localized regionally with high levels being detected in the cerebral cortex, basal ganglia and some mid- and hindbrain nuclei. Specific 125I-BH-CCK binding was also localized to the substantia gelatinosa of the rat, monkey and human spinal cord. L-365,260 inhibited binding to most areas of the brain, but in the rat medial nucleus tractus solitarii and the monkey nucleus tractus solitarii. dorsomedial nucleus and infundibular hypothalamic nuclei together with the dorsomedial aspects of the caudate nucleus, where CCK-A sites are present, L-365,260 failed to displace all 125I-BH-CCK binding. In the primate spinal cord, L-365,260 was a relatively weak inhibitor of 125I-BH-CCK binding (pIC50 congruent to 6.0) whereas MK-329 showed high affinity for the CCK-A sites present there (pIC50 congruent to 9.6).(ABSTRACT TRUNCATED AT 250 WORDS)
authors: Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, UK.
authors: D R
authors: DR
authors: Hill
authors: G N
authors: GN
authors: Woodruff
mesh_terms: D000818:Animals; D001345:Autoradiography; D001570:Benzodiazepinones / Q000494:pharmacology*; D002540:Cerebral Cortex / Q000187:drug effects; D002766:Cholecystokinin / Q000037:antagonists & inhibitors*; D020109:Devazepide; D006801:Humans; D008252:Macaca fascicularis; D008297:Male; D015394:Molecular Structure; D009928:Organ Specificity / Q000502:physiology; D010179:Pancreas / Q000187:drug effects; D010671:Phenylurea Compounds; D011869:Radioligand Assay; D051381:Rats; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors*; D013045:Species Specificity; D013116:Spinal Cord / Q000187:drug effects
chemical_list: D001570:Benzodiazepinones; D010671:Phenylurea Compounds; D011949:Receptors, Cholecystokinin; C058121:L 365260; D002766:Cholecystokinin; D020109:Devazepide